Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Finding the right unprofitable companies is difficult, which is why we started StockStory - to help you navigate the market. Keeping that in mind, here are three unprofitable companiesthat don’t make the cut and some better opportunities instead.
Bark (BARK)
Trailing 12-Month GAAP Operating Margin: -8.2%
Making a name for itself with the BarkBox, Bark (NYSE: BARK) specializes in subscription-based, personalized pet products.
Why Do We Think BARK Will Underperform?
- Sales trends were unexciting over the last five years as its 5.2% annual growth was below the typical consumer discretionary company
- Negative free cash flow raises questions about the return timeline for its investments
- Unfavorable liquidity position could lead to additional equity financing that dilutes shareholders
Bark’s stock price of $9.00 implies a valuation ratio of 24.3x forward EV-to-EBITDA. If you’re considering BARK for your portfolio, see our FREE research report to learn more.
Baldwin Insurance Group (BWIN)
Trailing 12-Month GAAP Operating Margin: -5.1%
Rebranded from BRP Group in May 2024, Baldwin Insurance Group (NASDAQ: BWIN) is an independent insurance distribution company that provides tailored insurance, risk management, and employee benefits solutions to businesses and individuals.
Why Is BWIN Not Exciting?
- Cash-burning history makes us doubt the long-term viability of its business model
- 6× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
Baldwin Insurance Group is trading at $20.14 per share, or 9.1x forward P/E. Read our free research report to see why you should think twice about including BWIN in your portfolio.
Invesco (IVZ)
Trailing 12-Month GAAP Operating Margin: -13.3%
With roots dating back to 1935 when it pioneered the first mutual fund with an objective of capital growth, Invesco (NYSE: IVZ) is a global asset management firm that offers investment solutions across equities, fixed income, alternatives, and multi-asset strategies.
Why Should You Dump IVZ?
- Sales were flat over the last five years, indicating it’s failed to expand this cycle
- Sales over the last five years were less profitable as its earnings per share fell by 1.1% annually while its revenue was flat
- 6× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
At $28.09 per share, Invesco trades at 10.7x forward P/E. Check out our free in-depth research report to learn more about why IVZ doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
